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Inflammaging is characterized by the upregulation of the inflammatory response that occurs with advancing age;
its roots are strongly embedded in evolutionary theory.
Inflammaging is believed to be a consequence of a remodelling of the innate and acquired immune system,
resulting in chronic inflammatory cytokine production.
Complex interrelated genetic, environmental and age-related factors determine an individual’s vulnerability or
resilience to inflammaging. These factors include polymorphisms to the promoter regions of cytokines, cytokine
receptors and antagonists, age-related decreases in autophagy and increased adiposity. Anti-inflammaging
describes the upregulation of the hypothalamic-pituitary axis in response to inflammaging, leading to higher levels
of cortisol, which in turn may be detrimental, contributing to less successful ageing and frailty. This may be
countered by the adrenal steroid dehydroepiandrosterone, which itself declines with age, leaving certain individuals
more vulnerable. Inflammaging and anti-inflammaging have both been linked with a number of age-related
outcomes, including chronic morbidity, functional decline and mortality. This important area of research offers
unique insights into the ageing process and the potential for screening and targeted interventions.
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Introduction
The immune system protects an organism from disease.
The first reference to immunity dates back to the plague
of Athens in 430 BC when it was noticed that people who
recovered from the disease could then nurse others with-
out contracting it a second time. It is recognized that the
immune system, comprising both innate (nonspecific) and
acquired (specific) components, is an intricate defence
system that is highly conserved across vertebrate species,
and has, from an evolutionary perspective, undergone
strong pressures to maximize survival to allow pro-
creation. The significant improvements in human survival
and lifespan to well beyond childbearing ages have been
totally ‘unpredicted’ by evolution. As a consequence,
human immune systems are exposed to considerable
additional antigenic exposure outside the forces of natural
selection. It is in this situation that immunity begins to* Correspondence: db@mrc.soton.ac.uk
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reproduction in any medium, provided the orexert negative effects on human ageing (antagonistic
pleiotropy), leading to gradual systemic failures [1,2].
The immune system of older people declines in relia-
bility and efficiency with age, resulting in greater suscep-
tibility to pathology as a consequence of inflammation, for
example, cardiovascular disease, Alzheimer's disease, auto-
reactivity and vaccine failure, as well as an increased
vulnerability to infectious disease [3-5]. These changes are
further compounded by reduced responsiveness and im-
paired communication between all cells of the immune
system. The overall change to the immune system with
age is termed immunosenescence and has a multifactorial
aetiology; a consequence of the complexity of the immune
system as well as of multiple genetic and environmental
influences [3]. Immunosenescence of the innate immune
system is primarily characterized by reduced cellular
superoxide production and capability for phagocytosis. In-
volution of the thymus and reduced responsiveness to
new antigen load, owing to reduced naïve: memory cell
ratio and expansion of mature cell clones, characterizes
immunosenescence of the acquired immune system
(Table 1).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Age-related changes to the immune system, adapted from [3]
Immune system Cell type Age–related changes
Innate immunity Neutrophils Reduced phagocytic ability of opsonized bacteria and impaired superoxide
production
Monocytes or macrophages Reduced levels of MHC class II complexes, reduced phagocytic ability and impaired
superoxide production
Dendritic cells Impaired capability to phagocytose apoptotic cells; impaired migration
Natural killer cells Reduced cytotoxicity
Acquired immunity T cells Thymus atrophy
Reduced naïve cells leaving thymus, severely contracted T-cell repertoire after 70
years
Impaired expansion and differentiation
Increased proinflammatory cytokine release, reduced IL-2 production
Increased memory and effector cells
Impaired T-cell help of B cells
Reduced regulatory T cells; possible increased inflammation and autoreactivity
Expanded clones of herpes virus (for example, cytomegalovirus) CD8+ cells,
dominating the T-cell repertoire and limiting response to other pathogens
B cells Reduced number of mature B cells leaving bone marrow
Increased memory B cells, decline in naïve B- cells
Reduced responsiveness to stimulatory molecules
Impaired antibody response to vaccination
MHC, major histocompatibility complex.
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tem is gathering pace as its importance within the context
of multiple pathologies in ageing populations is realized.
As part of this advance, Franceschi and colleagues [6]
described the phenomenon of ‘inflammaging’ at the turn
of the millennium as part of the spectrum of immuno-
senescence. Inflammaging denotes an upregulation of the
inflammatory response that occurs with age, resulting in a
low-grade chronic systemic proinflammatory state. It is
characterized by raised levels of proinflammatory cyto-
kines interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour
necrosis factor (TNF); all of which have been shown to
rise with age [7] and be involved in the pathogenesis of
most age-associated diseases [8]. C-reactive protein (CRP),
an acute phase protein produced by the liver in response to
IL-6, is also a useful marker of inflammaging, more com-
monly used in clinical practice, as well as a robust predictor
of risk for cardiovascular and other diseases [9,10].
Inflammaging
Inflammaging is believed to be a consequence of a cumu-
lative lifetime exposure to antigenic load caused by both
clinical and subclinical infections as well as exposure to
noninfective antigens [1]. The consequent inflammatory
response, tissue damage and production of reactive oxy-
gen species that cause oxidative damage also elicits the
release of additional cytokines, principally from cells of
the innate immune system [11] but also from the acquiredimmune response. This results in a vicious cycle, driving
immune system remodelling and favouring a chronic
proinflammatory state where pathophysiological changes,
tissue injury and healing proceed simultaneously. Irrevers-
ible cellular and molecular damage that is not clinically
evident slowly accumulates over decades (Figure 1).
Immunosenescence of the acquired system has received
a great deal of attention in recent years and is by a cellular
‘exhaustion’, which can contribute to inflammaging.
Thymic output is reduced with age resulting in reduced
T-cell repertoire and increased oligoclonal expansion of
memory and effector-memory cells [12]. This imbalance
results in a reduced ability to clear novel pathogens
(prolonging infection duration) as well as an increase in
functionally distinct T-cell populations, which have an
amplified proinflammatory phenotype [13]. The CD8+
T cell population is altered to a greater extent than the
CD4+ population and is associated with specificity to sin-
gle antigens, particularly latent viral infections, such as
cytomegalovirus, Epstein-Barr and varicella zoster virus.
Increases in numbers of antigen-specific cells with age are
associated with an increase in the number of terminally
differentiated ‘senescent’ cells, which occupy a large pro-
portion of immune space. These cells, particularly CD8+,
are extremely potent producers of inflammatory cytokines
and have been heavily associated with reduced antiviral
immunity and inflammatory related pathologies [14]. With
























Figure 1 Cycle of inflammaging.
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and TNF than their younger counterparts [15]. Subse-
quently antigenic load is a known driver of immuno-
senescence and has been associated with increased IL-6
and mortality [16]. Although it was recently shown that
cytomegalovirus infection did not drive inflammaging
(IL-6, TNF and CRP) in healthy older people over a 10-
year period, the study could not account for other latent
infections, suggesting a combined role of other antigenic
stimulus in systemic inflammaging [17]. Therefore, T-cell
immunosenescence is characterized by an increased pro-
inflammatory phenotype and most probably contributes
to inflammaging in a manner dependent on previous
exposure to and reactivation of antigenic challenges and
exhaustion of T-cell repertoire.
Of the innate immune system, monocytes and ma-
crophages are suggested to contribute to inflammaging
more than any other cell type. Monocyte changes with age
contribute to inflammaging by a functional shift towards a
proinflammatory phenotype and reduced function [18].
Monocytes consist of three distinct subtypes, differentiated
by expression of CD14 and CD16; CD14++/CD16− (clas-
sical), CD14++/CD16+ (intermediate) and CD14+/CD16++
(nonclassical), with varying degrees of functional capabi-
lities [19]. The CD16+ positive monocytes constitutively
produce more IL-6, IL-1β and TNF basally and with sti-
mulation, with older people having a significantly larger
proportion of CD16+ cells than younger people [20,21].
Furthermore, the CD16+ population have increased adher-
ence and migrate towards endothelial lesions via CX3CR1,
contributing to increased atheroma plaque formation [22].
Subsequently, monocytes can contribute to inflammaging
by chronically increased production of inflammatory cyto-
kines and prolongation of the immune response.
A two-hit hypothesis states that the extent to which an
individual is vulnerable to inflammaging and its physio-
logical consequences is dependent first on the degree of
increased proinflammatory environment and then on the
resilience of that individual to withstand it. This is
reflected in part by the balance of increasing levels ofproinflammatory cytokines with anti-inflammatory cyto-
kines, and also concentrations of soluble cytokine re-
ceptors and cytokine receptor antagonists. These are
believed to affect the degree to which an individual is sus-
ceptible to an antigenic load, the rate at which age-related
pathologies progress and individual vulnerability to frailty
[2,7] (Figure 2). Indeed, centenarians, a population deemed
to have aged successfully, have strong and effective anti-
inflammatory responses with a reduced proinflammatory
capacity [23]. This degree of susceptibility is multifactorial
and a consequence of complex genetic and environmental
interactions as well as of the ageing process itself.
Factors influencing susceptibility to inflammaging
There is now convincing evidence that susceptibility to
inflammaging is, in part, genetically determined through
polymorphisms of promoter regions of genes that either
affect cytokine production rates or alter their protein
structure to produce a functional variant. For example,
polymorphisms in the promoter C/G 174 on the IL-6
gene have been shown to affect serum IL-6 concentra-
tions [24]. Similar associations have been found in alleles
for IL-10 [25] and polymorphisms of the toll-like recep-
tor 4 residing on the membrane of dendritic cells. Mac-
rophages positively affect inflammatory responses and
are associated with an increased risk of acute myocardial
infarction [26].
Telomeres may also be implicated; these are protein
complexes made from several thousand repetitive DNA
sequences located at the end of chromosomes to protect
them from deterioration or fusion. Telomere repetitive se-
quences shorten with each cell division, eventually
reaching a critical number leading to cellular senescence
and death. There is evidence that this process is associated
with inflammation, although this is controversial, and the
direction of this relationship is unclear and could be bi-
directional. For example, raised IL-6 and TNF was associ-
ated with shorter telomere length in 1,962 individuals of
the Health, Ageing and Body Composition Study [27].
















Figure 2 Relationship between pro- and anti-inflammation and ageing.
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kidney and lung [28]. Negative relationships with telomere
length have also been demonstrated with CRP [29] and
IL-6 [30].
Ageing is associated with decreases in autophagy me-
chanisms, further contributing to proinflammatory envi-
ronments [31]. Autophagy is a cellular housekeeping
mechanism that is responsible for the removal of dysfunc-
tional intracellular protein (for example, dead organelles,
damaged scaffold proteins) via lysomal degradation. This
prevents the activation of inflammasomes; intracellular
multi-protein sensors that stimulate the inflammatory
response after recognizing danger signals emanating from
proteins, such as the intracellular danger-associated mo-
lecular patterns that occur as a consequence of either
tissue injury or necrosis. The consequence of a decline of
autophagy with age is therefore an increased activation of the
inflammasome and greater proinflammatory responses [32].
Ageing, though often visually characterized by a de-
crease in subcutaneous tissue and sarcopenia [33], is asso-
ciated with a linear accumulation of adipose tissue, both
around the viscera and via the fatty infiltration of several
organs, including liver, bone and muscle. This adipose
tissue, once thought of as inert, is now considered a major
endocrine and paracrine organ [34]; to date, approxi-
mately one hundred adipokines have been identified,
falling into several functional groups [35]; many are
proinflammatory. For example, the classic adipokine,
leptin, not only has a primary role in energy homeostasis
but also causes the stimulation and differentiation of
monocytes into macrophages, activates NK-lymphocytes
and induces the production of a number of proinfla-
mmatory cytokines, including TNF and IL-6 [36].
Consequently, greater degrees of adiposity are directly as-
sociated with greater proinflammatory environments,
partly via proinflammatory adipokines and also from im-
mune cells residing within adipose tissue.Anti-inflammaging
As with all complex organisms, single biological systems
rarely work in isolation. There is extensive cross-talk be-
tween the immune and endocrine axes, which, together
with the neural system, form the major communication
network in the body [37].
Cortisol is a glucocorticoid hormone secreted by the ad-
renal gland in response to pituitary secretion of adrenal
corticotrophic hormone, which itself is stimulated by cor-
ticotrophin releasing hormone from the hypothalamus;
together these form the hypothalamic-pituitary-adrenal
(HPA) axis. Cortisol plays key roles in the stress response
and is also immunosuppressive [38]. Neuronal cells within
the HPA axis contain multiple cytokine receptors, particu-
larly for IL-1, IL-6 and TNF [39], and it has been demon-
strated in human beings in vivo that injection of IL-6 or
TNF induces a marked change in HPA axis [40]. There-
fore, an inevitable physiological response to inflammaging
is an increase in circulating cortisol levels [41].
This mechanism has been termed anti-inflammaging
and although it represents an appropriate attempt to
counter the inflammaging process it may also have nega-
tive implications. These include the paradox of both
inflammaging and the global immunosuppression seen
with increasing age, as well as associations with frailty
via catabolic effects on several tissue types, such as liver
(gluconeogenesis), muscle (protein catabolism) and bone
(resorption) [41].
Dehydroepiandrosterone (DHEA) and its sulphated
precursor, DHEA sulphate (DHEAS), have opposing ac-
tions to cortisol and may protect individuals from the
negative effects of anti-inflammaging. They are secreted
from the adrenal cortex and, in smaller amounts from
the testis and ovary, although subsequently converted to
sex steroids in the latter; they account for 30% to 50% of
testosterone in men and 100% of oestrogen in post-
menopausal women. Like cortisol, DHEAS is also
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but serum levels are more stable as a consequence of
stronger binding to albumin [42]. Circulating DHEAS
concentrations reach a maximum in early adulthood and
subsequently decline with age to approximately 10% to
20% of maximal levels by 70 years [43]. There is large
interindividual variability in circulating DHEAS concen-
trations; some post-menopausal women have barely de-
tectable serum concentrations whilst others have normal
values. The fall in DHEAS is accompanied by a parallel
fall in androgens, resulting in women with low DHEAS
levels experiencing a deficit of sex steroids for their
remaining lifetime and negative implications for the age-
ing process [43].
More recently, an immunomodulating role for DHEAS
has been realized [38]; low levels are associated with
chronic inflammatory conditions and the molecule
counteracts the effects of cortisol via antagonism of
glucocorticoid receptors, either directly or via its down-
stream metabolites. Further, DHEAS may directly inhibit
glucocorticoid receptor production. This importance as
a counterbalance to cortisol has been demonstrated in a
number of in-vitro studies where the immunosup-
pression of neutrophil function that occurs with cortisol
has been successfully overcome by co-incubation with
DHEAS [44]. Additionally, a number of studies have
consistently demonstrated the steroid to be an enhancer
of IL-2 secretion from T-helper 1 (Th1) cells whilst ne-
gatively affecting secretion from T-helper 2 (Th2) cells.
Therefore, it has been suggested that observed declines in
DHEAS levels with age, at least in part, explains the cyto-
kine dysregulation seen with age and specifically the shift
towards Th2 cytokine profiles.
From this discussion it is apparent that both cortisol
and DHEAS have opposing effects relating to the immune
system. Cortisol causes immune-suppression and its con-












Figure 3 Representation of changes in adrenocorticoid hormones witthe effects of cortisol and is immune modulating, and its
concentration falls with age. Therefore, when considering
the effects of the HPA axis on inflammaging, the ratio of
cortisol to DHEAS (Figure 3) may more accurately reflect
the HPA axis than either cortisol or DHEAS alone. An
in-vivo study of cortisol and DHEAS in patients with sep-
tic shock after a hip fracture showed that higher cortisol
levels, lower DHEAS levels, and a higher cortisol: DHEAS
ratio correlated with poorer clinical outcomes [45]. This
ratio has also been positively associated with metabolic
syndrome and all-cause, cancer and other medical cause
mortality in Vietnam veterans [38,46].
Cortisol: DHEAS ratios have the potential for manipu-
lation via DHEAS supplementation. To date, DHEAS
supplementation has been trialled in a number of chronic
inflammatory conditions, usually with nonbeneficial out-
comes. However, doses used have always been low. The
only true beneficial effect of DHEAS supplementation has
been seen in patients with systemic lupus erythematosus,
where the drug successfully reduces disease activity and
the number of exacerbations [47-49].
Associations with chronic disease and ageing
Inflammaging, in particular elevations in levels of TNF,
IL-6, IL-1 and CRP, are strong independent risk factors
for morbidity and mortality in older people [50]. Epi-
demiological and mechanistic studies suggest that many
age-related diseases are initiated or worsened by sys-
temic inflammation, including neurodegeneration and
atherosclerosis [51,52]. For example, proinflammatory
cytokines have been shown to interact with the process-
ing and production of Aβ peptide, the pathological hall-
mark feature of Alzheimer’s disease, and autopsy studies
have shown that the brains of patients who had Alzheimer’s
disease have dramatically higher levels of proinflammatory
markers than high-pathology controls who have pathological
features of Alzheimer’s disease without its symptoms [53].Increasing age
Cortisol: DHEAS ratio
h age.
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within myocytes, causing a shift towards catabolism, atro-
phy and progression of sarcopenia; this is a major con-
tributor to functional decline and frailty. As with other
age-related disease processes, it is believed that the degree
of shift towards catabolism affects the rate of sarcopenic
decline, and cachexia in older people may represent this
process in extremis. Proinflammatory cytokines appear to
play a particularly important role through activation of
NF-κB and the ubiquitin system which is implicated in
myofibre proteolysis [54]. It may be that interindividual
variations in vulnerability to inflammaging in part explain
the different rates at which individuals become sarcopenic.
A number of community-based observational studies have
demonstrated associations between proinflammatory cyto-
kine profiles and sarcopenia. For example, cross-sectional
analysis from the InCHIANTI study (1,020 men and
women over 65 years) demonstrated a significant associ-
ation between inflammation (IL-6, IL-1R, CRP) and both
poor physical performance and reduced muscle strength
[55]. Longitudinal associations also exist. Schaap used data
from 2,177 men and women, (mean age 73), to show sig-
nificant associations between TNF and 5-year change in
muscle mass [56]. Associations with sarcopenia have also
been demonstrated in the Framingham Heart Study (IL-6)
[57] and the Longitudinal Aging Study Amsterdam (IL-6,
CRP) [58] and have recently undergone systematic review
[59]. Inflammaging is also implicated in the progression of
osteoporosis [60] and dementia [51]; both strongly impli-
cated in the frailty syndrome.
Higher cortisol levels have been associated with in-
creased mortality in patients with stroke [61], sepsis [62],
heart failure [63] and sarcopenia [64]. Low levels of DHEA
have been demonstrated in patients with chronic inflam-
matory diseases, including inflammatory bowel disease,
rheumatoid arthritis, systemic lupus erythematosus and
pemphigus [65]. Moreover, associations have also been
established between low DHEAS concentrations and car-
diovascular disease, sarcopenia, osteoporosis and all-cause
mortality [66-68].
The cumulative consequence of having a greater de-
gree of inflammaging and anti-inflammaging is increased
susceptibility to, and a faster progression of, all age-
related diseases. This results in an increased vulnerabil-
ity to stressors and reduced functional ability and is
associated with the development of the frailty syndrome
[50]. Interestingly, a 10-year study of 254 healthy,
community-dwelling older people demonstrated that
those individuals with baseline markers of greater
inflammaging (white cell count) and anti-inflammaging
(cortisol to DHEAS ratio) were significantly more likely
to be frail at 10-year follow-up. Intriguingly, the authors
speculate that this might offer a tool to screen for people
who are ‘less robust’ in late middle age to allow earlyintervention before functional decline and the develop-
ment of frailty [50].
Conclusions
Inflammaging is a pathological phenomenon and a central
concept that brings together our understanding of age-
related chronic disease, functional decline and frailty across
the lifecourse. It is a consequence of lifelong exposure
of the immune system to antigenic stimuli and complex
genetic, environmental and age-related mechanisms that
expose varying degrees of vulnerability or resilience. An im-
portant consequence of inflammaging is activation of the
HPA axis, anti-inflammaging and a widening of the gap be-
tween molar concentrations of cortisol and DHEA(S). This
‘double-edged’ sword provides an appropriate counter to
inflammaging but also has multi-system consequences in
terms of disease progression and immunosuppression.
As populations age, a better understanding of these
processes is essential to identify older people who are at
risk of ageing-related chronic diseases, in order to facili-
tate successful, early, targeted interventions.
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